Edecrin® (ethacrynic acid) – First-Time Generic

- On June 30, 2016, Edenbridge Pharmaceuticals announced the FDA approval of an AB-rated generic version of Aton/Valeant's Edecrin (ethacrynic acid) 25 mg tablets.

- Edecrin is also available generically as ethacrynate sodium intravenous solution.

- Edecrin is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required:
  - Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.
  - Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema.
  - Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome.

- In addition to the oral indications for Edecrin, intravenous ethacrynate sodium is indicated when a rapid onset of diuresis is desired, eg, in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable.

- Edenbridge will begin shipping generic Edecrin on July 8, 2016.